Annual CFI
-$165.80 M
+$881.08 M+84.16%
31 December 2023
Summary:
Sarepta Therapeutics annual cash flow from investing activities is currently -$165.80 million, with the most recent change of +$881.08 million (+84.16%) on 31 December 2023. During the last 3 years, it has fallen by -$661.22 million (-133.47%). SRPT annual CFI is now -133.47% below its all-time high of $495.41 million, reached on 31 December 2021.SRPT Cash From Investing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFI
-$128.82 M
-$30.30 M-30.75%
30 September 2024
Summary:
Sarepta Therapeutics quarterly cash flow from investing activities is currently -$128.82 million, with the most recent change of -$30.30 million (-30.75%) on 30 September 2024. Over the past year, it has dropped by -$64.47 million (-100.17%). SRPT quarterly CFI is now -140.13% below its all-time high of $321.06 million, reached on 30 June 2021.SRPT Quarterly CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFI
-$72.92 M
+$81.75 M+52.85%
30 September 2024
Summary:
Sarepta Therapeutics TTM cash flow from investing activities is currently -$72.92 million, with the most recent change of +$81.75 million (+52.85%) on 30 September 2024. Over the past year, it has increased by +$92.89 million (+56.02%). SRPT TTM CFI is now -114.72% below its all-time high of $495.41 million, reached on 31 December 2021.SRPT TTM CFI Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
SRPT Cash From Investing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | -100.2% | +56.0% |
| 3 y3 years | -133.5% | -4899.0% | -114.7% |
| 5 y5 years | -157.8% | -854.2% | -125.4% |
SRPT Cash From Investing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -133.5% | +84.2% | -158.9% | +83.6% | -114.7% | +93.1% |
| 5 y | 5 years | -133.5% | +84.2% | -140.1% | +83.6% | -114.7% | +93.1% |
| alltime | all time | -133.5% | +84.2% | -140.1% | +83.6% | -114.7% | +93.1% |
Sarepta Therapeutics Cash From Investing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$128.82 M(+30.7%) | -$72.92 M(-52.9%) |
| June 2024 | - | -$98.53 M(-145.0%) | -$154.66 M(-481.9%) |
| Mar 2024 | - | $218.80 M(-440.0%) | $40.50 M(-124.4%) |
| Dec 2023 | -$165.80 M(-84.2%) | -$64.36 M(-69.4%) | -$165.80 M(+80.9%) |
| Sept 2023 | - | -$210.57 M(-317.9%) | -$91.65 M(-166.4%) |
| June 2023 | - | $96.63 M(+673.6%) | $138.04 M(-155.5%) |
| Mar 2023 | - | $12.49 M(+27.5%) | -$248.58 M(-76.3%) |
| Dec 2022 | -$1.05 B(-311.3%) | $9.80 M(-48.8%) | -$1.05 B(-1.2%) |
| Sept 2022 | - | $19.12 M(-106.6%) | -$1.06 B(+0.1%) |
| June 2022 | - | -$289.99 M(-63.1%) | -$1.06 B(+136.7%) |
| Mar 2022 | - | -$785.81 M(>+9900.0%) | -$447.06 M(-190.2%) |
| Dec 2021 | $495.41 M(-507.0%) | -$2.58 M(-112.7%) | $495.41 M(+32.4%) |
| Sept 2021 | - | $20.27 M(-93.7%) | $374.10 M(-8.3%) |
| June 2021 | - | $321.06 M(+104.9%) | $407.91 M(+675.1%) |
| Mar 2021 | - | $156.67 M(-226.5%) | $52.63 M(-143.2%) |
| Dec 2020 | -$121.72 M(-142.5%) | -$123.89 M(-329.1%) | -$121.72 M(-732.3%) |
| Sept 2020 | - | $54.08 M(-258.0%) | $19.25 M(-136.5%) |
| June 2020 | - | -$34.23 M(+93.6%) | -$52.78 M(-139.4%) |
| Mar 2020 | - | -$17.68 M(-203.5%) | $133.81 M(-53.3%) |
| Dec 2019 | $286.73 M(-177.4%) | $17.08 M(-195.1%) | $286.73 M(+798.6%) |
| Sept 2019 | - | -$17.96 M(-111.8%) | $31.91 M(-335.8%) |
| June 2019 | - | $152.37 M(+12.7%) | -$13.53 M(-93.9%) |
| Mar 2019 | - | $135.23 M(-156.9%) | -$221.00 M(-40.3%) |
| Dec 2018 | -$370.49 M(+107.2%) | -$237.74 M(+275.0%) | -$370.49 M(-40.9%) |
| Sept 2018 | - | -$63.40 M(+15.1%) | -$626.45 M(+43.0%) |
| June 2018 | - | -$55.09 M(+286.3%) | -$438.10 M(+8.7%) |
| Mar 2018 | - | -$14.26 M(-97.1%) | -$403.06 M(+125.4%) |
| Dec 2017 | -$178.81 M(+98.3%) | -$493.69 M(-495.1%) | -$178.81 M(-254.0%) |
| Sept 2017 | - | $124.95 M(-723.1%) | $116.11 M(+8307.4%) |
| June 2017 | - | -$20.05 M(-109.6%) | $1.38 M(-98.6%) |
| Mar 2017 | - | $209.99 M(-205.6%) | $100.37 M(-211.3%) |
| Dec 2016 | -$90.19 M(-1172.4%) | -$198.77 M(-2044.2%) | -$90.19 M(-332.7%) |
| Sept 2016 | - | $10.22 M(-87.0%) | $38.76 M(-34.9%) |
| June 2016 | - | $78.94 M(+306.4%) | $59.56 M(-472.3%) |
| Mar 2016 | - | $19.42 M(-127.8%) | -$15.99 M(-290.2%) |
| Dec 2015 | $8.41 M(-105.3%) | -$69.82 M(-325.1%) | $8.41 M(-93.3%) |
| Sept 2015 | - | $31.02 M(+816.9%) | $124.91 M(+70.3%) |
| June 2015 | - | $3.38 M(-92.3%) | $73.35 M(+9.3%) |
| Mar 2015 | - | $43.83 M(-6.1%) | $67.09 M(-142.2%) |
| Dec 2014 | -$159.03 M(+1262.5%) | $46.68 M(-327.2%) | -$159.03 M(-23.0%) |
| Sept 2014 | - | -$20.54 M(+614.0%) | -$206.53 M(+10.1%) |
| June 2014 | - | -$2.88 M(-98.4%) | -$187.66 M(+0.8%) |
| Mar 2014 | - | -$182.29 M(>+9900.0%) | -$186.24 M(+1495.6%) |
| Dec 2013 | -$11.67 M(+919.4%) | -$822.00 K(-51.0%) | -$11.67 M(+3.5%) |
| Sept 2013 | - | -$1.68 M(+15.4%) | -$11.27 M(+16.5%) |
| June 2013 | - | -$1.45 M(-81.2%) | -$9.68 M(+12.5%) |
| Mar 2013 | - | -$7.72 M(+1725.1%) | -$8.60 M(+651.4%) |
| Dec 2012 | -$1.15 M(-50.3%) | -$423.00 K(+422.2%) | -$1.15 M(-24.0%) |
| Sept 2012 | - | -$81.00 K(-78.6%) | -$1.51 M(-13.7%) |
| June 2012 | - | -$379.00 K(+44.7%) | -$1.75 M(-21.8%) |
| Mar 2012 | - | -$262.00 K(-66.6%) | -$2.23 M(-3.2%) |
| Dec 2011 | -$2.31 M(+17.5%) | -$784.00 K(+145.0%) | -$2.31 M(+13.7%) |
| Sept 2011 | - | -$320.00 K(-63.0%) | -$2.03 M(-7.7%) |
| June 2011 | - | -$865.00 K(+157.4%) | -$2.20 M(+22.6%) |
| Mar 2011 | - | -$336.00 K(-33.7%) | -$1.79 M(-8.6%) |
| Dec 2010 | -$1.96 M | -$507.00 K(+3.7%) | -$1.96 M(-19.1%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2010 | - | -$489.00 K(+6.3%) | -$2.42 M(+7.0%) |
| June 2010 | - | -$460.00 K(-8.9%) | -$2.27 M(+8.4%) |
| Mar 2010 | - | -$505.00 K(-47.9%) | -$2.09 M(+10.9%) |
| Dec 2009 | -$1.88 M(+52.0%) | -$969.00 K(+192.7%) | -$1.88 M(+39.3%) |
| Sept 2009 | - | -$331.00 K(+16.5%) | -$1.35 M(+12.3%) |
| June 2009 | - | -$284.00 K(-5.0%) | -$1.20 M(+1.5%) |
| Mar 2009 | - | -$299.00 K(-31.6%) | -$1.19 M(-4.4%) |
| Dec 2008 | -$1.24 M(-111.7%) | -$437.30 K(+139.4%) | -$1.24 M(-114.1%) |
| Sept 2008 | - | -$182.70 K(-31.3%) | $8.79 M(+7.4%) |
| June 2008 | - | -$266.00 K(-24.6%) | $8.19 M(-17.5%) |
| Mar 2008 | - | -$353.00 K(-103.7%) | $9.92 M(-6.2%) |
| Dec 2007 | $10.58 M(-632.0%) | $9.59 M(-1317.1%) | $10.58 M(+1563.9%) |
| Sept 2007 | - | -$788.20 K(-153.6%) | $635.60 K(-20.0%) |
| June 2007 | - | $1.47 M(+390.8%) | $794.10 K(-162.3%) |
| Mar 2007 | - | $299.70 K(-186.4%) | -$1.27 M(-35.9%) |
| Dec 2006 | -$1.99 M(-81.8%) | -$346.90 K(-44.9%) | -$1.99 M(-81.9%) |
| Sept 2006 | - | -$629.70 K(+5.3%) | -$10.98 M(+17.9%) |
| June 2006 | - | -$597.90 K(+44.6%) | -$9.31 M(-16.1%) |
| Mar 2006 | - | -$413.50 K(-95.6%) | -$11.10 M(+1.7%) |
| Dec 2005 | -$10.92 M(-152.4%) | -$9.34 M(-998.1%) | -$10.92 M(-278.0%) |
| Sept 2005 | - | $1.04 M(-143.5%) | $6.13 M(-49.0%) |
| June 2005 | - | -$2.39 M(+938.3%) | $12.04 M(-49.2%) |
| Mar 2005 | - | -$230.00 K(-103.0%) | $23.70 M(+13.7%) |
| Dec 2004 | $20.84 M(-234.8%) | $7.71 M(+11.1%) | $20.84 M(+112.8%) |
| Sept 2004 | - | $6.94 M(-25.2%) | $9.79 M(+168.9%) |
| June 2004 | - | $9.28 M(-399.7%) | $3.64 M(-116.8%) |
| Mar 2004 | - | -$3.10 M(-7.1%) | -$21.66 M(+40.1%) |
| Dec 2003 | -$15.46 M(+544.2%) | -$3.33 M(-521.0%) | -$15.46 M(+40.2%) |
| Sept 2003 | - | $791.70 K(-104.9%) | -$11.03 M(+26.3%) |
| June 2003 | - | -$16.02 M(-615.5%) | -$8.73 M(+782.3%) |
| Mar 2003 | - | $3.11 M(+183.2%) | -$989.30 K(-58.8%) |
| Dec 2002 | -$2.40 M(-81.2%) | $1.10 M(-64.5%) | -$2.40 M(-82.3%) |
| Sept 2002 | - | $3.09 M(-137.3%) | -$13.58 M(-22.8%) |
| June 2002 | - | -$8.29 M(-587.7%) | -$17.60 M(+76.7%) |
| Mar 2002 | - | $1.70 M(-116.8%) | -$9.96 M(-22.0%) |
| Dec 2001 | -$12.77 M(+1065.3%) | -$10.08 M(+988.5%) | -$12.77 M(+314.9%) |
| Sept 2001 | - | -$926.40 K(+43.8%) | -$3.08 M(+22.8%) |
| June 2001 | - | -$644.40 K(-42.1%) | -$2.51 M(+18.7%) |
| Mar 2001 | - | -$1.11 M(+183.5%) | -$2.11 M(+92.7%) |
| Dec 2000 | -$1.10 M(+119.1%) | -$392.90 K(+10.6%) | -$1.10 M(+36.5%) |
| Sept 2000 | - | -$355.30 K(+42.3%) | -$802.80 K(+46.6%) |
| June 2000 | - | -$249.70 K(+155.3%) | -$547.50 K(+37.6%) |
| Mar 2000 | - | -$97.80 K(-2.2%) | -$397.80 K(-20.4%) |
| Dec 1999 | -$500.00 K(-80.8%) | -$100.00 K(0.0%) | -$500.00 K(-16.7%) |
| Sept 1999 | - | -$100.00 K(0.0%) | -$600.00 K(-76.0%) |
| June 1999 | - | -$100.00 K(-50.0%) | -$2.50 M(-7.4%) |
| Mar 1999 | - | -$200.00 K(0.0%) | -$2.70 M(+3.8%) |
| Dec 1998 | -$2.60 M(+420.0%) | -$200.00 K(-90.0%) | -$2.60 M(-3.7%) |
| Sept 1998 | - | -$2.00 M(+566.7%) | -$2.70 M(+285.7%) |
| June 1998 | - | -$300.00 K(+200.0%) | -$700.00 K(+16.7%) |
| Mar 1998 | - | -$100.00 K(-66.7%) | -$600.00 K(+20.0%) |
| Dec 1997 | -$500.00 K(-600.0%) | -$300.00 K(<-9900.0%) | -$500.00 K(+150.0%) |
| Sept 1997 | - | $0.00(-100.0%) | -$200.00 K(0.0%) |
| June 1997 | - | -$200.00 K(<-9900.0%) | -$200.00 K(<-9900.0%) |
| Mar 1997 | - | $0.00 | $0.00 |
| Dec 1996 | $100.00 K | - | - |
FAQ
- What is Sarepta Therapeutics annual cash flow from investing activities?
- What is the all time high annual CFI for Sarepta Therapeutics?
- What is Sarepta Therapeutics quarterly cash flow from investing activities?
- What is the all time high quarterly CFI for Sarepta Therapeutics?
- What is Sarepta Therapeutics quarterly CFI year-on-year change?
- What is Sarepta Therapeutics TTM cash flow from investing activities?
- What is the all time high TTM CFI for Sarepta Therapeutics?
- What is Sarepta Therapeutics TTM CFI year-on-year change?
What is Sarepta Therapeutics annual cash flow from investing activities?
The current annual CFI of SRPT is -$165.80 M
What is the all time high annual CFI for Sarepta Therapeutics?
Sarepta Therapeutics all-time high annual cash flow from investing activities is $495.41 M
What is Sarepta Therapeutics quarterly cash flow from investing activities?
The current quarterly CFI of SRPT is -$128.82 M
What is the all time high quarterly CFI for Sarepta Therapeutics?
Sarepta Therapeutics all-time high quarterly cash flow from investing activities is $321.06 M
What is Sarepta Therapeutics quarterly CFI year-on-year change?
Over the past year, SRPT quarterly cash flow from investing activities has changed by -$64.47 M (-100.17%)
What is Sarepta Therapeutics TTM cash flow from investing activities?
The current TTM CFI of SRPT is -$72.92 M
What is the all time high TTM CFI for Sarepta Therapeutics?
Sarepta Therapeutics all-time high TTM cash flow from investing activities is $495.41 M
What is Sarepta Therapeutics TTM CFI year-on-year change?
Over the past year, SRPT TTM cash flow from investing activities has changed by +$92.89 M (+56.02%)